KZR - Kezar Life Sciences, Inc.
| Previous Close | 3.2300 |
| Open | 3.2100 |
| Bid | 3.0600 x 1300 |
| Ask | 4.0500 x 800 |
| Day's Range | 3.0600 - 3.2100 |
| 52 Week Range | 2.3600 - 22.5000 |
| Volume | 66,618 |
| Avg. Volume | 131,477 |
| Market Cap | 59.328M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Nov 05, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.67 |
- GlobeNewswire
Kezar Life Sciences Enhances Clinical Expertise with the Appointment of Elizabeth Garner, MD, MPH to its Board of Directors
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the appointment of Elizabeth Garner, MD, MPH to its Board of Directors. Dr. Garner is currently the Chief Medical Officer of ObsEva SA. “Beth’s addition to the board brings a wealth of clinical development, regulatory, and medical affairs experience,” said Jean-Pierre Sommadossi, PhD, Chairman of the Board at Kezar.
- Insider Monkey
Hedge Funds Are Selling Kezar Life Sciences, Inc. (KZR)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- GlobeNewswire
Kezar Life Sciences Highlights Therapeutic Potential of Protein Secretion Inhibitors at the 61st American Society of Hematology Annual Meeting
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, highlighted work from its research and development platform focusing on Sec61 translocon inhibition during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, FL from December 7-10, 2019. Two oral presentations and one poster presentation focus on novel inhibitors of the Sec61 translocon, which demonstrate high degrees of potency against a large number of therapeutically relevant oncology and immuno-oncology targets that are Sec61 client proteins, translating into broad anti-tumor activity.
- GlobeNewswire
Kezar Life Sciences to Present at the Piper Jaffray 31st Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
- Simply Wall St.
What Type Of Shareholder Owns Kezar Life Sciences, Inc.'s (NASDAQ:KZR)?
Every investor in Kezar Life Sciences, Inc. (NASDAQ:KZR) should be aware of the most powerful shareholder groups...
- GlobeNewswire
Kezar Life Sciences to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
- GlobeNewswire
Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting
Step-up dose titration lowered GI side effects while maintaining clinical activityMajority of patients completing 13 weeks of treatment demonstrated significant improvement on.
- GlobeNewswire
Kezar Life Sciences to Host Conference Call and Webcast during the American College of Rheumatology Annual Meeting to Discuss Updated Results with KZR-616
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
- GlobeNewswire
Kezar Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update
Additional data from the ongoing Phase 1b portion of the MISSION study to be presented at the 2019 ACR/ARP Meeting in Atlanta, GAPhase 2 MISSION, PRESIDIO, and MARINA trials.
- ACCESSWIRE
Kaskela Law LLC Announces Investigation of Kezar Life Sciences, Inc. (KZR) on Behalf of Investors
PHILADELPHIA, PA / ACCESSWIRE / October 28, 2019 / Kaskela Law LLC is investigating Kezar Life Sciences, Inc. ("Kezar" or the "Company") (Nasdaq:KZR) on behalf of the Company's investors. ...
- GlobeNewswire
Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
- GlobeNewswire
Kezar Life Sciences to Present at the 2019 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2019 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
- GlobeNewswire
Kezar Life Sciences Announces Presentations at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
- GuruFocus.com
Frazier Management Llc Buys Translate Bio Inc, Kezar Life Sciences Inc
Investment company Frazier Management Llc (Current Portfolio) buys Translate Bio Inc, Kezar Life Sciences Inc during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Frazier Management Llc. Continue reading...
- GlobeNewswire
Kezar Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update
Promising data reported from the Phase 1b portion of MISSION, a first-in-patient study of KZR-616; Phase 2 portion of MISSION in LN patients has been initiatedPhase 2 PRESIDIO.
- PR Newswire
Shareholder Rights Law Firm Johnson Fistel Launches Investigations
SAN DIEGO , July 2, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims for violations of federal law against the following companies that recently issued ...
- Benzinga
The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs June 12) • Abbott Laboratories (NYSE: ABT ) • Avedro ...
- GlobeNewswire
Kezar Life Sciences Announces Promising Data from First in Patient Study of KZR-616 at EULAR 2019 Annual Meeting
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced positive results from the Phase 1b open-label dose escalation portion of the MISSION study evaluating KZR-616 in patients with systemic lupus erythematosus (SLE). The primary objective of this first-in-patient study is to assess the safety and tolerability of KZR-616. “We are encouraged by the early safety and efficacy data for KZR-616.
- GlobeNewswire
Kezar Life Sciences to Host Conference Call and Webcast at the EULAR 2019 Annual Meeting to Discuss Results of First in Patient Study with KZR-616
SOUTH SAN FRANCISCO, Calif., June 10, 2019 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
- Benzinga
The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 28) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Arrowhead ...
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Kezar Life Sciences, Inc. - KZR
Pomerantz LLP is investigating claims on behalf of investors of Kezar Life Sciences, Inc. (“Kezar” or the “Company”) (KZR). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. Following this news, Kezar’s stock price fell $6.99 per share, or 41.39%, to close at $9.90 per share on May 28, 2019.
- GlobeNewswire
Kezar Life Sciences Announces Acceptance of Abstract for Presentation of First in Patient Study with KZR-616 at EULAR 2019 Annual Meeting
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that data from the first two cohorts of an open-label dose escalation trial of KZR-616 in patients with systemic lupus erythematosus (SLE) will be featured in a poster presentation at the European League Against Rheumatism (EULAR) 2019 annual meeting taking place in Madrid, Spain June 12-15. The full abstract, which is published on EULAR’s conference website, features preliminary results from the first two cohorts of the Phase 1b portion of the MISSION trial (Modulator of the Immunoproteasome for Systemic Lupus with and without Nephritis), which is evaluating KZR-616 in patients with SLE. Additional details regarding the trial, outcome measures, and patients enrolled will be presented at the meeting.
- Simply Wall St.
Did Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Buy Up More Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
